...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell metabolism >Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
【24h】

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes

机译：噻唑烷二酮与2型糖尿病患者胰岛素增敏的前景

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current antidiabetic agents that function primarily by increasing insulin sensitivity. However, despite clear benefits in glycemic control, this class of drugs has recently fallen into disuse due to concerns over side effects and adverse events. Here we review the clinical data and attempt to balance the benefits and risks of TZD therapy. We also examine potential mechanisms of action for the beneficial and harmful effects of TZDs, mainly via agonism of the nuclear receptor PPARγ. Based on critical appraisal of both preclinical and clinical studies, we discuss the prospect of harnessing the insulin sensitizing effects of PPARγ for more effective, safe, and potentially personalized treatments of type 2 diabetes.
机译：2型糖尿病是由胰岛素抵抗以及无法产生足够的胰岛素来控制血糖引起的，噻唑烷二酮（TZDs）是目前仅有的主要通过增加胰岛素敏感性发挥作用的抗糖尿病药。然而，尽管在控制血糖方面有明显的好处，但由于担心副作用和不良事件，这类药物最近已被废弃。在这里，我们回顾了临床数据，并试图平衡TZD治疗的益处和风险。我们还研究了主要通过核受体PPARγ的激动作用对TZD的有益和有害作用的潜在作用机理。基于对临床前和临床研究的严格评估，我们讨论了利用PPARγ的胰岛素增敏作用进行更有效，安全和潜在的2型糖尿病治疗的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号